FIELD: physics.
SUBSTANCE: invention relates to determination of complement-dependent cytotoxicity of the composition. Method for determining complement-dependent cytotoxicity of a composition comprising a first binding site which specifically binds to a first epitope of a first antigen conjugated to a first human Fc region polypeptide, and a second binding site that specifically binds to a second epitope of the second antigen conjugated with a second polypeptide of the human Fc region, includes the following steps: incubation of a human cell expressing a first antigen or a first antigen and a second antigen, with a composition, adding to a mixture of step (a) rabbit complement, determining cell lysis and thereby determining the complement-dependent cytotoxicity of the composition.
EFFECT: invention provides an improved test for determining complement-dependent cytotoxicity.
12 cl, 4 dwg, 13 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODIES | 2011 |
|
RU2573588C2 |
| ANTIBODIES AGAINST CCR7 RECEPTOR FOR CANCER TREATMENT | 2006 |
|
RU2404808C2 |
| ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6 | 2012 |
|
RU2676731C2 |
| ANTIBODIES SPECIFIC TO CLAUDIN 6 (CLDN6) | 2010 |
|
RU2675997C2 |
| ANTIBODIES FOR TREATING CANCER, IN WHICH CLAUDIN 6 IS EXPRESSED | 2012 |
|
RU2816850C2 |
| THERAPEUTIC ANTIBODIES | 2012 |
|
RU2616881C2 |
| MONOCLONAL ANTI-CLAUDIN-18 ANTIBODIES FOR TREATING CANCER | 2008 |
|
RU2571923C2 |
| METHOD FOR SELECTION AND OBTAINING OF HIGHLY SELECTIVE AND MULTISPECIFIC TARGETING GROUPS WITH SPECIFIED PROPERTIES, INCLUDING AT LEAST TWO DIFFERENT BINDING GROUPS, AND THEIR APPLICATIONS | 2013 |
|
RU2639287C2 |
| METHODS AND COMPOSITIONS FOR IMPROVING EFFECTIVENESS OF ANTIBODY FOR MEDICAL APPLICATION WITH USING COMPOUNDS POTENTIATING NK-CELLS | 2004 |
|
RU2396981C2 |
| CANCER TREATMENT USING TARGETED ANTIBODIES IN VIVO | 2011 |
|
RU2642305C2 |
